Does the media prefer RCUS or BIOA?

In the previous week, BioAge Labs had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Arcus Biosciences. BioAge Labs' average media sentiment score of 0.72 beat Arcus Biosciences' score of 0.42 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BEAM or BIOA?

In the previous week, Beam Therapeutics and Beam Therapeutics both had 4 articles in the media. Beam Therapeutics' average media sentiment score of 0.96 beat BioAge Labs' score of 0.72 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNGX or BIOA?

In the previous week, BioAge Labs had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat BioAge Labs' score of 0.72 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BIOA or GMTX?

BioAge Labs currently has a consensus target price of $43.50, indicating a potential upside of 169.20%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAge Labs 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer DYN or BIOA?

In the previous week, Dyne Therapeutics had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Dyne Therapeutics and 4 mentions for BioAge Labs. Dyne Therapeutics' average media sentiment score of 0.87 beat BioAge Labs' score of 0.72 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioAge Labs (BIOA) Competitors

$16.15 -0.39 (-2.37%)

As of 02:21 PM Eastern

Compare

BIOA vs. RCUS, BEAM, TNGX, GMTX, and DYN

Should you buy BioAge Labs stock or one of its competitors? MarketBeat compares BioAge Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAge Labs include Arcus Biosciences (RCUS), Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), Gemini Therapeutics (GMTX), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry.

How does BioAge Labs compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

BioAge Labs has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.06	-$353M	-$3.18	N/A
BioAge Labs	$8.99M	79.90	-$80.61M	-$2.40	N/A

Arcus Biosciences presently has a consensus target price of $33.89, indicating a potential upside of 43.09%. BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 169.20%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Arcus Biosciences has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 20.8% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioAge Labs had 1 more articles in the media than Arcus Biosciences. MarketBeat recorded 4 mentions for BioAge Labs and 3 mentions for Arcus Biosciences. BioAge Labs' average media sentiment score of 0.72 beat Arcus Biosciences' score of 0.42 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcus Biosciences has a net margin of -156.36% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

BioAge Labs beats Arcus Biosciences on 12 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Beam Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than BioAge Labs. Beam Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.56	-$79.99M	-$0.68	N/A
BioAge Labs	$8.99M	79.90	-$80.61M	-$2.40	N/A

99.7% of Beam Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 20.8% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Beam Therapeutics and Beam Therapeutics both had 4 articles in the media. Beam Therapeutics' average media sentiment score of 0.96 beat BioAge Labs' score of 0.72 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics currently has a consensus target price of $46.83, suggesting a potential upside of 59.93%. BioAge Labs has a consensus target price of $43.50, suggesting a potential upside of 169.20%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Beam Therapeutics has a net margin of -39.66% compared to BioAge Labs' net margin of -871.75%. Beam Therapeutics' return on equity of -29.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

Beam Therapeutics beats BioAge Labs on 11 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tango Therapeutics presently has a consensus target price of $32.27, indicating a potential upside of 51.03%. BioAge Labs has a consensus target price of $43.50, indicating a potential upside of 169.20%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts plainly believe BioAge Labs is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BioAge Labs has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	54.24	-$101.59M	-$0.83	N/A
BioAge Labs	$8.99M	79.90	-$80.61M	-$2.40	N/A

In the previous week, BioAge Labs had 2 more articles in the media than Tango Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat BioAge Labs' score of 0.72 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a net margin of -151.15% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
BioAge Labs	-871.75%	-29.40%	-27.26%

Tango Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

BioAge Labs beats Tango Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Gemini Therapeutics?

BioAge Labs (NASDAQ:BIOA) and Gemini Therapeutics (NASDAQ:GMTX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

BioAge Labs currently has a consensus target price of $43.50, indicating a potential upside of 169.20%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts plainly believe BioAge Labs is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

75.4% of Gemini Therapeutics shares are held by institutional investors. 20.8% of BioAge Labs shares are held by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BioAge Labs had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for BioAge Labs and 0 mentions for Gemini Therapeutics. BioAge Labs' average media sentiment score of 0.72 beat Gemini Therapeutics' score of 0.00 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Overall Sentiment
BioAge Labs	Positive
Gemini Therapeutics	Neutral

BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market.

Gemini Therapeutics has lower revenue, but higher earnings than BioAge Labs. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	79.90	-$80.61M	-$2.40	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Gemini Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

BioAge Labs beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and BioAge Labs (NASDAQ:BIOA) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 20.8% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dyne Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
BioAge Labs	-871.75%	-29.40%	-27.26%

BioAge Labs has higher revenue and earnings than Dyne Therapeutics. BioAge Labs is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
BioAge Labs	$8.99M	79.90	-$80.61M	-$2.40	N/A

Dyne Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Dyne Therapeutics presently has a consensus target price of $35.00, suggesting a potential upside of 97.75%. BioAge Labs has a consensus target price of $43.50, suggesting a potential upside of 169.20%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Dyne Therapeutics had 2 more articles in the media than BioAge Labs. MarketBeat recorded 6 mentions for Dyne Therapeutics and 4 mentions for BioAge Labs. Dyne Therapeutics' average media sentiment score of 0.87 beat BioAge Labs' score of 0.72 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dyne Therapeutics beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$718.98M	$2.98B	$4.28B	$12.43B
Dividend Yield	N/A	15.15%	7.92%	5.29%
P/E Ratio	-6.74	13.13	21.83	24.23
Price / Sales	79.90	3,055.06	134.22	125.38
Price / Cash	N/A	28.32	56.86	57.88
Price / Book	2.13	6.15	32.55	6.71
Net Income	-$80.61M	-$40.32M	$109.80M	$337.09M
7 Day Performance	-4.67%	0.33%	-0.05%	0.63%
1 Month Performance	-3.76%	2.20%	4.12%	5.15%
1 Year Performance	N/A	19.75%	16.27%	34.36%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
BIOA BioAge Labs	3.5873 of 5 stars	$16.16 -2.3%	$43.50 +169.2%	N/A	$718.98M	$8.99M	N/A	N/A
RCUS Arcus Biosciences	2.5685 of 5 stars	$23.48 +0.2%	$33.89 +44.4%	+165.3%	$2.95B	$247M	N/A	500
BEAM Beam Therapeutics	2.3268 of 5 stars	$28.64 flat	$46.83 +63.5%	+78.9%	$2.95B	$139.74M	N/A	510
TNGX Tango Therapeutics	2.9189 of 5 stars	$20.24 flat	$32.27 +59.5%	+746.5%	$2.93B	$56.99M	N/A	90
GMTX Gemini Therapeutics	N/A	$66.82 -0.5%	N/A	+54.2%	$2.90B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. RCUS, BEAM, TNGX, GMTX, and DYN

How does BioAge Labs compare to Arcus Biosciences?

Summary

How does BioAge Labs compare to Beam Therapeutics?

Summary

How does BioAge Labs compare to Tango Therapeutics?

Summary

How does BioAge Labs compare to Gemini Therapeutics?

Summary

How does BioAge Labs compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. RCUS, BEAM, TNGX, GMTX, and DYN

How does BioAge Labs compare to Arcus Biosciences?

Which has better valuation & earnings, RCUS or BIOA?

Do analysts prefer RCUS or BIOA?

Which has more volatility & risk, RCUS or BIOA?

Do institutionals & insiders believe in RCUS or BIOA?

Does the media prefer RCUS or BIOA?

Is RCUS or BIOA more profitable?

Summary

How does BioAge Labs compare to Beam Therapeutics?

Which has more risk & volatility, BEAM or BIOA?

Which has better valuation & earnings, BEAM or BIOA?

Do insiders & institutionals have more ownership in BEAM or BIOA?

Does the media refer more to BEAM or BIOA?

Do analysts recommend BEAM or BIOA?

Is BEAM or BIOA more profitable?

Summary

How does BioAge Labs compare to Tango Therapeutics?

Do insiders and institutionals believe in TNGX or BIOA?

Do analysts recommend TNGX or BIOA?

Which has higher valuation & earnings, TNGX or BIOA?

Does the media prefer TNGX or BIOA?

Is TNGX or BIOA more profitable?

Which has more risk and volatility, TNGX or BIOA?

Summary

How does BioAge Labs compare to Gemini Therapeutics?

Do analysts rate BIOA or GMTX?

Do institutionals and insiders believe in BIOA or GMTX?

Does the media favor BIOA or GMTX?

Which has more volatility and risk, BIOA or GMTX?

Which has higher earnings and valuation, BIOA or GMTX?

Is BIOA or GMTX more profitable?

Summary

How does BioAge Labs compare to Dyne Therapeutics?

Do institutionals & insiders have more ownership in DYN or BIOA?

Is DYN or BIOA more profitable?

Which has higher valuation & earnings, DYN or BIOA?

Which has more volatility & risk, DYN or BIOA?

Do analysts rate DYN or BIOA?

Does the media prefer DYN or BIOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools